Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | OXTR | P30559 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18843922 | 0.93 | MEN1 (0.39) | TP53GAAALDH1A1TSHRNPSR1 | |
| SCHEMBL321121 | 0.92 | TP53 (0.37) | TP53GAAALDH1A1TSHRNPSR1 | |
| SCHEMBL14934454 | 0.91 | MAPK1 (0.42) | TP53GAAALDH1A1TSHRHDAC8 | |
| SCHEMBL16177509 | 0.88 | GAA (0.40) | TP53GAAALDH1A1TSHRHDAC8 | |
| SCHEMBL320548 | 0.83 | MAPK1 (0.39) | TP53GAAALDH1A1TSHRKMT2A | |
| SCHEMBL19613845 | 0.83 | SOS1 (0.40) | TP53GAAALDH1A1TSHRNPSR1 | |
| SCHEMBL14934460 | 0.82 | ALDH1A1 (0.36) | TP53GAAALDH1A1TSHRRORC | |
| SCHEMBL14921462 | 0.82 | CNR1 (0.47) | TP53GAAALDH1A1TSHRNPSR1 | |
| SCHEMBL14921470 | 0.81 | ALDH1A1 (0.40) | ALDH1A1TSHRHDAC8KMT2AKDM4E | |
| SCHEMBL1094098 | 0.81 | KDM4E (0.37) | TP53GAAALDH1A1TSHRRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316026-B2 | Method for removing dimethoxybenzyl group | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-06-11 | — | — | US | disclosed |
| US-10316026-B2 | Method for removing dimethoxybenzyl group | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-06-11 | — | — | US | disclosed |
| EP-3372583-A1 | METHOD FOR REMOVING DIMETHOXYBENZYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-09-12 | — | — | EP | disclosed |
| US-20180251448-A1 | METHOD FOR REMOVING DIMETHOXYBENZYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-09-06 | — | — | US | disclosed |
| WO-2017078123-A1 | METHOD FOR REMOVING DIMETHOXYBENZYL GROUP | 第一三共株式会社 | 2017-05-11 | — | — | WO | disclosed |
| US-9630929-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2017-04-25 | — | — | US | disclosed |
| US-9630929-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2017-04-25 | — | — | US | disclosed |
| US-9630929-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2017-04-25 | — | — | US | disclosed |
| EP-2773637-B1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2016-06-08 | — | — | EP | disclosed |
| EP-2773637-B1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2016-06-08 | — | — | EP | disclosed |
| US-20140296245-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2014-10-02 | — | — | US | disclosed |
| US-20140296245-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2014-10-02 | — | — | US | disclosed |
| US-20140296245-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2014-10-02 | — | — | US | disclosed |
| WO-2013064983-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251448-A1 | METHOD FOR REMOVING DIMETHOXYBENZYL GROUP | DDT, ALKBH5, DDO | TP53 713/4885GAA 2164/4885ALDH1A1 1602/4885 |
| US-20140296245-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV1, TRPA1, TRPV3 | TP53 1018/4885GAA 1392/4885ALDH1A1 2347/4885 |
| US-10316026-B2 | Method for removing dimethoxybenzyl group | DDT, ALKBH5, DDO | TP53 713/4885GAA 2164/4885ALDH1A1 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.